Advertisement

Hämostase und Hämotherapie

  • Sabine H. Quentin
  • J. Rathgeber
  • M. Köhler
Chapter
  • 77 Downloads

Zusammenfassung

Unter »Hämotherapie« wird die Behandlung mit Arzneimitteln zum Ausgleich eines Mangels oder zum Ersatz von Blut oder Blutbestandteilen verstanden. Überwiegend befasst sich die Hämotherapie daher mit der Anwendung von Blutkomponenten, aber auch mit Alternativtherapeutika, wie z. B. Hormonen oder Wachstumsfaktoren.

Literatur

  1. 1.
    Alperin JB (1987) Coagulopathy caused by vitamin K deficiency in critically ill, hospitalized patients. JAMA 258: 1916–1919PubMedCrossRefGoogle Scholar
  2. 2.
    American Society of Anesthesiologists Task Force on Blood Component therapy (1996) Practice guidelines for blood component therapy. Anesthesiology 84: 732–747Google Scholar
  3. 3.
    Andreu G, Dewaillyi (1994) Prevention of HLA alloimmunisation by using leukocyte-depleted components.Curr Stud hematol BloodTransfus 60: 29Google Scholar
  4. 4.
    Arbeitskreis Blut, Untergruppe »Bewertung Blutassoziierter Krankheitserreger» (1999) Human T-cell lymphotropic viruses type 1 and 2 ( HTLV-I/-II ). Infus Ther Transfus Med 26: 321–326Google Scholar
  5. 5.
    BaglinT(1996) Disseminated intravascular coagulation: diagnosis and treatment. BMJ 312: 683–687Google Scholar
  6. 6.
    Baudo F, DeGasperi A, deCataldo F, Caimi TM, Cattaneo D, Raedelli R, Pannaciulli E, Corti A, Mazza E, Belli L (1992) Antithrombin Ill supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial.Thromb Res 68: 409–416Google Scholar
  7. 7.
    Baudo F, Caimi TM, de Cataldo F et al. (1998) Antithrombin Ill (AT Ill) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 224: 336–342CrossRefGoogle Scholar
  8. 8.
    Baughman RP, Lower EE, Flessa HC, Tollerud DJ (1993) Thrombocytopenia in the intensive care unit. Chest 104: 1243–1247PubMedCrossRefGoogle Scholar
  9. 9.
    Bernard GR, Vincent VL, Laterre PF et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699–709PubMedCrossRefGoogle Scholar
  10. 10.
    Beschluss des 100. Deutschen Ärztetages in Eisenach (1997) (Muster-) Berufsordnung für die deutschen Ärztinnen und Ärzte. Dtsch Ärztebl 94: A-2354Google Scholar
  11. 11.
    Beutler E (1993) Platelet transfusion: The 20,000/4 trigger. Blood 81: 1411–1413.PubMedGoogle Scholar
  12. 12.
    Blauhut B, Lundsgard-Hansen P (1988) Akuter Blutverlust und Verbrennungen in der operativen Medizin. ln:Transfusionsmedizin ( 1. Auflage) Mueller-Eckhardt C (Hrsg ). Springer Berlin-New York pp 280–321CrossRefGoogle Scholar
  13. 13.
    Bonfiglio MF, Traeger SM, Kier KL, Martin BR, Hulisz DT, Verbeck SR (1995) Thrombocytopenia in intensive care patients: a comprehensive analysis of risk factors in 314 patients. Ann Pharmacother 29: 835–42PubMedGoogle Scholar
  14. 14.
    Bordin JO et al. (1994) Biologic effects of leucocytes present in transfused cellular blood products. Blood 84: 1703–1721PubMedGoogle Scholar
  15. 15.
    Bowden RA, Slichter SJ, Sayers M et al. (1995) A comparison of filtered leucocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86: 3598–3603Google Scholar
  16. 16.
    Budde U, Pötzsch B (1998) Von-Willebrand-Faktor und von-Willebrand-Erkrankung. In: Müller-Berghaus G, Plötsch B (Hrsg) Hämostaseologie. Springer, Berlin Heidelberg New York Tokio, S 228–238Google Scholar
  17. 17.
    Bundesinstitut für Arzneimittel und Medizinprodukte (1996) 3. Bekanntmachung zur Anzeige von Nebenwirkungen, Wechselwirkungen, Wechselwirkungen mit anderen Mitteln und Arzneimittelmißbrauch nach § 29 Abs. 1 Satz 2 bis 8 AMG. Bundesgesundheitsblatt 11/96, 39: 439–445Google Scholar
  18. 18.
    Burroughs SF, Johnson GJ (1990) Beta-lactam antibiotic-inducedGoogle Scholar
  19. 19.
    Carson JL, Duff A, Poses RM et al. (1996) Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet 348: 1055–1060PubMedCrossRefGoogle Scholar
  20. 20.
    Chang H et al. (2000) Allogenetic red blood transfusion is an independent risk factor for the development of postoperative bacterial infection. Vox Sang 78: 13–18PubMedCrossRefGoogle Scholar
  21. 21.
    Ciavarella D, Reed RL, Counts RB et al. (1987) Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol 67: 365–368PubMedCrossRefGoogle Scholar
  22. 22.
    Collins JA (1976) Massive blood transfusion. Clin Haematol 5: 201222Google Scholar
  23. 23.
    Dahr W (1996) Blutgruppen von Erythrozyten. In: Mueller-Eckhardt C (Hrsg) Transfusionsmedizin. Springer, Berlin Heidelberg New York, 5137–162Google Scholar
  24. 24.
    De Vries JX, Schmitz-Kummer E, Weber E (1998) Pharmakologie der oralen Antikoagulanzien vom Cumarintyp. In: Müller-Berghaus G, Pötzsch B (Hrsg) Hämostaseologie. Springer, Berlin Heidelberg New York Tokio, S 662–665Google Scholar
  25. 25.
    Furie B, Bouchard BA, Furie BC (1999) Vitamin K-dependent biosynthesis of y-carboxyglutamic acid. Blood 93: 1798–1808PubMedGoogle Scholar
  26. 26.
    George JN, Shattil SJ (1991) The clinical importance of acquired abnormalities of platelet function. N Engl J Med 324: 27–39PubMedCrossRefGoogle Scholar
  27. 27.
    Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz) vom 11. Dezember 1998, Bundesgesetzblatt 15.3586; Zehnte Novelle, Bundesgesetzblatt I, S. 1002, Juli 2000Google Scholar
  28. 28.
    Gesetz zur Regelung des Transfusionswesens (Transfusionsgesetz) vom 1. Juli 1998. Bundesgesetzblatt I, S. 1752 ff.Google Scholar
  29. 29.
    Glück D, Kubanek B, Ahnefeld FW (1986) Die Therapie mit Blutkomponenten.Voraussetzungen, Indikationen und klinische Anwendung. Infusionsther 13: 240–249Google Scholar
  30. 30.
    Glück D, Kubanek B, Maurer C, Petersen N (1998) Seroconversion of HIV, HCV, and HBV inblood donors in 1996 - Risk of transmission by blood products in Germany. A multicenter study of the Berufsverband Deutscher Transfusionsmediziner e.V. Infusionsther Transfusionsmed 25: 82–84Google Scholar
  31. 31.
    Graul A, Keller-Stanislawski B (1999) Hamovigilanz von Blutkomponenten. Bundesgesundheistblatt 42: 143–149CrossRefGoogle Scholar
  32. 32.
    Hanes SD, Quarles DA, Boucher BA (1997). Incidence and risk factors of thrombocytopenia in critically ill trauma patients. Ann Pharmacother 31: 285–289PubMedGoogle Scholar
  33. 33.
    Hebert PC, Wells G, Blajchman M et al., and the Transfusion Requirements in Critical Care Investigators for the Canadian Critical Care Trial Group (1999) A multicenter, randomized, conrolled clinical trial of transfusion requirements in critical care. N Engl J Med 340: 409–417Google Scholar
  34. 34.
    Hewitt PE, Machin SJ (1990) Massive blood transfusion. BMJ 300: 107–109PubMedCrossRefGoogle Scholar
  35. 35.
    Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H (1995) Oral anticoagulants- Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 108 (Suppl): 231–246CrossRefGoogle Scholar
  36. 36.
    Hopkins KD (2001) Complement faktor H and the haemolytic uraemic syndrome. Lancet 358: 1200–1202CrossRefGoogle Scholar
  37. 37.
    Jensen LS, Kissmeyer-Nielsen P, Wolff B, Qvist N (1996) Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 348: 841–845PubMedCrossRefGoogle Scholar
  38. 38.
    Kaufman DW, Kelly JP, Johannes CB et al. (1993) Acute thrombocytopenic purpura in relation to the use of drugs. Blood 82: 27142718Google Scholar
  39. 39.
    Köhler M, Seifried E, Hellstern Petal. (1988) In vivo recovery and half-life time of a steam-treated factor IX concentrate in haemophilia B patients- The influence of reagents and standards. Blut 57: 341345Google Scholar
  40. 40.
    Köhler M, Heiden M, Harbauer G, Miyashita C, Mörsdorf S, Braun B, Ernert P, Wenzel E, Rose S, Pindur G (1990) Comparison of different prothrombin complex concentrates: In vitro and in vivo studies. Thromb Res 60: 63–70Google Scholar
  41. 41.
    Köhler M, Wieding JU (1993) Roles of desmopressin and vasopressin in haemostasis. Gross P, Richter D, Robertson GL (eds) Vasopressin. John Libbey Eurotext, pp 441–454Google Scholar
  42. 42.
    Köhler M, Hellstem P, Lechler E, Überfuhr P, Müller-Berghaus G (1998) Thromboembolic complications associated with the use of pro-thrombin complex and factor IX concentrates.Thromb Haemostas 80: 399–402Google Scholar
  43. 43.
    Köhler M (1998) Desmopressin: Pharmakologie und Therapie. In: Müller-Berghaus G, Pötzsch B (Hrsg) Hämostaseologie. Springer, Berlin Heidelberg New York Tokio, S 67–71Google Scholar
  44. 44.
    Kyrie PA (1998) Thrombotische Mikroangiopathie. In: Müller-Berghaus G, Plötsch B (Hrsg) Hämostaseologie. Springer, Berlin Heidelberg New York Tokio, S 452–456Google Scholar
  45. 45.
    Lee GR (1998) Anaemia: General aspects. In: Lee GR et al. (eds) Wintrobe’s clinical hematology, 10th edn. Williams & Wilkins, BaltimoreGoogle Scholar
  46. 46.
    Leslie SD,Toy PTCY (1991) Laboratory abnormalities in massively transfused patients given red blood cells and crystalloid. Am J Clin Pathol 96: 770–773PubMedGoogle Scholar
  47. 47.
    Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston FE (1997) Emergency oral anticoagulant reversal:The relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy.Thromb Haemostas 77: 477–480Google Scholar
  48. 48.
    Mannucci PM, Franchi F, Dioguardi N (1976) Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet II: 542–545, 1976CrossRefGoogle Scholar
  49. 49.
    Mannucci PM, Federici AB, Sirchia G (1982) Hemostasis testing during massive blood replacement.A study of 172 cases. Vox Sang 42: 113–123PubMedCrossRefGoogle Scholar
  50. 50.
    Mannucci PM (1998) Hemostatic drugs. N Engl J Med 1998, 339: 245–253Google Scholar
  51. 51.
    Marlar RA, Montgomery RR, Broekmans AW (1989) Report on the diagnosis and treatment of homozygous protein Cdeficiency.Thromb Haemostas 61: 529–531Google Scholar
  52. 52.
    McCrea KR, Samuels P, Schreiber AD (1992) Pregnancy-associated thrombocytopenia: Pathogenesis and management. Blood 26972714Google Scholar
  53. 53.
    Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347: 589–600PubMedCrossRefGoogle Scholar
  54. 54.
    Montag T, Lange H, Schmidt U, Strobel J, Exner M (1999) Bakterielle Kontamination von Blutkomponenten. Bundesgesundheitsbl 42: 132–142CrossRefGoogle Scholar
  55. 55.
    Müller-Berghaus G (1997) Hämostatische Funktionen der Endothelzelle. Hämostaseologie 17: 78–85Google Scholar
  56. 56.
    Murray DJ, Olson J, Strauss R, Tinker JH (1988) Coagulation changes during packed red cell replacement of major blood loss. Anesthesiology 69: 839–845PubMedCrossRefGoogle Scholar
  57. 57.
    NovotnyVMJ (1999) Prevention and management of platelet transfusion refractoriness.Vox Sang 76: 1CrossRefGoogle Scholar
  58. 58.
    Oldenburg J, Brackmann HH (1998) Diagnostik, Klinik und Therapie der Hämophilie A. In: Müller-Berghaus G, Plötsch B (Hrsg) Hämostaseologie. Springer, Berlin Heidelberg New York Tokio, S 185–197Google Scholar
  59. 59.
    Owings JT, Bagkley M, Gosselin R, Romac D, Disbrow E (1996) Effect of critical injury of plasma antithrombin activity: Lowantithrombin levels are associated with thromboembolic complications. J Trauma 41: 396–406Google Scholar
  60. 60.
    Palareti G, Legnani C, Maccaferi M et al., and Members of the S. Orsola Working Group on Liver Transplantation (1991) Coagulation and fibrinolysis in orthotopic liver transplantation: role of recipient’s disease and use of antithrombin III concentrates. Haemostasis 21: 68–76Google Scholar
  61. 61.
    Palareti G, Leali N, Coccheri Set al. (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study. Lancet 348: 423–429PubMedCrossRefGoogle Scholar
  62. 62.
    Popovsky A, Saidman SL (1998) MGH case reports (Case 40–1998): A 49-year-old woman with thrombotic thrombocytopenic purpura and severe dyspnoe during plasmapheresis and transfusion. N Engl J Med 339: 2005–2012CrossRefGoogle Scholar
  63. 63.
    Popovsky MA, Moore SB (1985) Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 25: 573–577PubMedCrossRefGoogle Scholar
  64. 64.
    Popovsky MA, Haley NR (2000) Further characterization of transfusion-related acute lung injury: Demographics, clinical and laboratory features, and morbidity. Immunohematology 16: 157–159Google Scholar
  65. 65.
    Porte RJ (1993) Coagulation and fibrinolysis in orthotopic liver transplantation: current views and insights. Semin Thromb Haemost 19: 191–196CrossRefGoogle Scholar
  66. 66.
    Reed RL, Ciavarella D, Heimbach DM, Baron L, Pavlin E, Counts RB, CJ (1986) Prophylactic platelet administration massive transfusion. Ann Surg 203: 40–48Google Scholar
  67. 67.
    Rock GA, Shumak KH, Buskard NA et al., and the Canadian Apheresis Study Group (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325: 393–397Google Scholar
  68. 68.
    Sattler FR, Weitekamp MR, Sayegh A, Ballard JO (1988) Impaired hemostasis caused by beta-lactam antibiotics Am J Surg 155: 30–39Google Scholar
  69. 69.
    Schinzel H, Weilemann LS (1998) Antithrombin substitution therapy. Blood Coagul Fibrinolys 9 (Suppl 3): S17 - S22Google Scholar
  70. 70.
    Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ, for the Retrovirus Epidemiology Donor Study (1996) The Risk of transfusion-transmitted viral infections. N Engl J Med 334: 1685–1690Google Scholar
  71. 71.
    Shevchuk M, Conly JM (1990) Antibiotic hypoproteinemia: A review of prospective studies, 1966–1988. Rev Infect Dis 12: 1109–1126PubMedCrossRefGoogle Scholar
  72. 72.
    Smith OP, WhiteB, Vaughan D, Rafferty M, Claffey L, Lyons B, Casey W (1997) Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 350: 1590 1593Google Scholar
  73. 73.
    Spiess BD, Ley C, Body SC et al. (1998) Haematocrit value on intensive care unit entry influences the frequency of Q-wave myocardial infarction after coronary artery bypass grafting. The Institutions of the multicenter Study of Perioperative Ischemia ( McSPI) Research Group. J Thorac Cardiovasc Surg 116: 460–467Google Scholar
  74. 74.
    Van de Watering LMG, Hermans J, Houbiers JGA et al. (1998) Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery. Circulation 97: 562–568PubMedCrossRefGoogle Scholar
  75. 75.
    Vorstand und Wissenschaftlicher Beirat der Bundesärztekammer (2001) Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. 2. Aufl. Deutscher Ärzte-Verlag, KölnGoogle Scholar
  76. 76.
    Vorstand und Wissenschaftlicher Beirat der Bundesärztekammer ( 2002 Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. 2. Aufl. 2001 - Revision 2002; Dtsch Ärztebl 99 /49Google Scholar
  77. 77.
    Warren BL, Eid A, Singer P et al. (2001) High dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA 286: 18691878Google Scholar
  78. 78.
    Warren HS, Suffredini AF, Eichacker PQ, Munford RS (2002) Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 347: 1027–1030PubMedCrossRefGoogle Scholar
  79. 79.
    Wieding JU, Hellstem P, Köhler M (1993) Inaktivation of viruses in fresh-frozen plasma. Ann Haematol 67: 259–266CrossRefGoogle Scholar
  80. 80.
    Wissenschaftlicher Beirat der Bundesärztekammer und Paul-EhrlichInstitut (2000) Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Neu bearbeitete Fassung. Deutscher Ärzte-Verlag, KölnGoogle Scholar
  81. 81.
    Wissenschaftlicher Beirat der Bundesärztekammer und Paul-EhrlichInstitut (2001) Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Neuformulierungen und Kommentare. Dtsch Ärztebl 98 /46Google Scholar
  82. 82.
    Wolf CFW, Canale VC (1976) Fatal pulmonary hypersensitivy reaction to HLA-incompatible blood transfusion: Report of a case and review of the Iiterature.Transfusion 16: 135–140Google Scholar
  83. 83.
    Zindrou D, Taylor KM, Bagger JP (2002) Preoperative haemoglobin concentration and mortality rate after coronary artery bypass surgery. Lancet 359: 1747–1748PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Sabine H. Quentin
  • J. Rathgeber
  • M. Köhler

There are no affiliations available

Personalised recommendations